Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30241% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology cash
Cash and short-term investments held at the end of each period.
Champions Oncology's cash was $4.36M at Jul 31, 2026. For fiscal 2026 it was $4.87M, down 50.2% from the year before. Over ten years it grew 6.5% a year on average. The highest annual figure on record is $10.46M in fiscal 2011.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $4.87M | -50.2% |
| FY2025 | Apr 30, 2025 | $9.79M | +273.8% |
| FY2024 | Apr 30, 2024 | $2.62M | -74.1% |
| FY2023 | Apr 30, 2023 | $10.12M | +12.3% |
| FY2022 | Apr 30, 2022 | $9.01M | +92.2% |
| FY2021 | Apr 30, 2021 | $4.69M | -43.8% |
| FY2020 | Apr 30, 2020 | $8.34M | +157.7% |
| FY2019 | Apr 30, 2019 | $3.24M | +221.8% |
| FY2018 | Apr 30, 2018 | $1.01M | -70.8% |
| FY2017 | Apr 30, 2017 | $3.45M | +33.3% |
| FY2016 | Apr 30, 2016 | $2.59M | -72.4% |
| FY2015 | Apr 30, 2015 | $9.36M | +58.8% |
| FY2014 | Apr 30, 2014 | $5.89M | -38.4% |
| FY2013 | Apr 30, 2013 | $9.56M | +101.1% |
| FY2012 | Apr 30, 2012 | $4.75M | -54.5% |
| FY2011 | Apr 30, 2011 | $10.46M | +306.6% |
| FY2010 | Apr 30, 2010 | $2.57M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $4.36M | -57.8% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $4.87M | -50.2% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $7.13M | +122.6% |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | $8.52M | +209.2% |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | $10.33M | +257.0% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $9.79M | +273.8% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $3.20M | -28.3% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $2.75M | -50.0% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $2.89M | -40.6% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $2.62M | -74.1% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $4.47M | -61.6% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $5.51M | -49.1% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $4.87M | -39.6% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $10.12M | +12.3% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $11.65M | +33.8% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $10.83M | +126.4% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $8.06M | +101.6% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $9.01M | +92.2% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $8.70M | +17.1% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $4.78M | -44.1% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $4.00M | -42.4% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $4.69M | -43.8% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $7.43M | +126.4% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $8.55M | +207.2% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $6.94M | +215.3% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $8.34M | +157.7% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $3.28M | -0.8% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $2.78M | +42.3% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $2.20M | +88.9% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $3.24M | +221.8% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $3.31M | +211.7% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $1.96M | +196.4% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $1.17M | +101.0% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $1.01M | -70.8% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $1.06M | -69.6% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $660.00K | -84.8% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $580.00K | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $3.45M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $3.49M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $4.33M | – |
See a number that looks wrong?